1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Venus Remedies Limited

Venus Remedies Limited

1,396.30
INR
-42.85
(-2.98%)
86.92EPS
21.50P/E
24.97BMarket Cap
Venus Remedies Limited
BSE:VENUSREM
(Bombay Stock Exchange)

Recent

price

1,396.30

P/E

ratio

21.50

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
397.72
444.81
480.11
476.88
405.02
361.5
345.21
299.38
257.23
274.94
444.11
453.66
413.99
442.47
484.24
549.52
606.92
Revenue per Share
50.63
51.22
58.8
57.17
4.51
1.48
-14.88
-24.87
-23.16
-8.1
50.04
30.86
19.87
21.31
33.9
76.9
86.91
Basic EPS, GAAP
40.9
45.34
-53.25
-37.37
0.33
-3.12
11.17
25.27
28.69
56.57
106.82
31.15
21.55
17.78
51.14
88.33
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
259.52
315.43
359.63
403.43
399.13
349.34
314.92
293.23
269.43
262.01
324.33
329.5
344.38
364.74
419.65
496.56
- -
Book Value per Share
118.82
132.45
165.78
206.05
190.04
162.9
158.37
146.92
133.3
176.66
245.96
263.72
285.1
300.99
341.31
426.25
- -
Tangible Book Value per Share
9
9
10
11
11
11
11
12
12
12
12
13
13
13
13
13
13
Basic Weighted Avg Shares
3,631
4,088
4,679
5,363
4,635
4,149
3,963
3,695
3,174
3,393
5,481
5,986
5,534
5,914
6,473
7,345
8,113
Sales/Revenue/Turnover
19.69
19.12
18.62
17.7
9.36
9.54
2.69
1.53
-0.46
2.6
3.38
4.77
5.01
5.61
6.34
14.51
17.24
Operating Margin (%)
191
113
331
402
460
416
403
338
340
320
353
335
323
264
225
257
263
Depreciation Expense
462
471
573
643
52
17
-171
-307
-286
-100
618
407
266
285
453
1,028
1,162
Net Income, GAAP
12.19
7.42
8.8
6.92
- -
51.56
- -
- -
- -
- -
- -
- -
29.96
36.18
36.91
23.38
23.37
Effective Tax Rate (%)
12.73
11.52
12.25
11.99
1.11
0.41
-4.31
-8.31
-9
-2.95
11.27
6.8
4.8
4.82
7
13.99
14.32
Profit Margin (%)
138
151
343
611
704
839
626
299
18
694
1,366
1,853
2,403
2,801
2,606
2,334
- -
Working Capital
880
991
1,291
1,400
2,023
1,910
1,618
1,374
1,160
721
468
387
387
387
- -
110
- -
LT Debt
2,369
3,073
3,791
4,616
4,567
3,997
3,887
3,619
3,325
3,234
4,003
4,404
4,603
4,876
5,609
6,637
- -
Total Equity
19.45
11.98
9.73
9.18
- -
0.22
- -
- -
- -
- -
- -
- -
3.94
4.1
5.89
13.19
- -
Return on Invested Capital (%)
19.45
16.38
13.08
12.5
- -
2.31
- -
- -
- -
- -
- -
- -
5.41
5.54
8.31
16.6
- -
Return on Capital (%)
22.65
17.3
16.7
15.3
1.12
0.4
-4.33
-8.18
-8.23
-3.05
17.07
9.69
5.9
6.01
8.64
16.79
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
14
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
110
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
10,252
11,036
24,972

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,952
- -
Cash, Cash Equivalents & STI
- -
989
- -
Accounts Receivable, Net
- -
1,033
- -
Inventories
- -
1,294
- -
Total Current Liabilities
- -
1,618
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
14
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.71%
10.77%
18.33%
Free Cash Flow
2.88%
28.82%
72.71%
Net Income, GAAP
-169.11%
24.86%
126.83%
Sales/Revenue/Turnover
7.46%
6.29%
13.48%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,086
1,701
1,765
1,977
6,473
2026
1,372
1,928
1,803
2,594
7,345
2027
1,789
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.92
2.63
14.66
15.71
33.9
2026
7.18
15.06
19.14
35.53
76.9
2027
17.18
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Venus Remedies Limited (VENUSREM.NS), an Indian research-driven pharmaceutical company founded in 1989 and headquartered in Panchkula, Haryana, develops, manufactures and markets specialty injectable formulations focused on critical care segments including anti-infectives, oncology, neurology, cardiovascular, pain management and antimicrobial resistance solutions. The company offers a comprehensive portfolio of products such as carbapenem antibiotics including Potentox and Tobracef; oncology injectables like Topocan; anti-infectives including Sulbactomax, Cynoplex and Lastinem; pain management options like Pyrogesic infusion and Trois Nanotech Pain Relief Emulsion; neurology treatments such as Neurospark and Liracetam; cardiovascular drugs like Megaparin and Tero; and innovative formulations including Ampucare wound care and R3SET product line encompassing pain relief tablets, herbal detox candies and apple cider vinegar gummies; alongside intravenous fluids like DNS Solution and Isolyte P infusion. Venus Remedies operates three cGMP-compliant manufacturing facilities in India, exports to over 80 countries across emerging and developed markets including Southeast Asia, Europe, Africa and the Middle East with subsidiaries like Venus Pharma GmbH in Germany, and maintains 11 international marketing offices contributing more than 70% of its revenue from exports. Recent developments include an exclusive licensing agreement in February 2025 with Infex Therapeutics to develop and commercialize MET-X, a resistance-bypass treatment for Gram-negative infections paired with meropenem in India; new drug approvals in Vietnam in November 2025 expanding its ASEAN footprint to over 374 marketing authorizations; appointment of Akshansh Chaudhary as President of Venus Army and CTO; renewed GMP certification from Ukraine; joining the United Nations Global Compact; and introduction of a comprehensive family medical insurance policy for employees.